Opportunity Information: Apply for RFA AI 14 009
Apply for RFA AI 14 009
- The National Institutes of Health in the education health income security and social services sector is offering a public funding opportunity titled "U.S South Africa Program for Collaborative Biomedical Research (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research 93.399 Cancer Control 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research 93.865 Child Health and Human Development Extramural Research 93.989 International Research and Research Training.
- This funding opportunity was created on Dec 13, 2013 and posted on Dec 13, 2013.
- Applicants must submit their applications by Apr 22, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $8,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $350,000.00 in funding.
- Eligible applicants include: State governments County governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Private institutions of higher education Public housing authorities/Indian housing authorities Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Special district governments Native American tribal governments (Federally recognized) For profit organizations other than small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) from South Africa are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The U.S. South Africa Program for Collaborative Biomedical Research (R01) is a National Institutes of Health (NIH) grant opportunity created to build and support sustained, high-quality biomedical research partnerships between investigators and institutions in the United States and South Africa. The program is structured around the NIH R01 mechanism, meaning it is intended for well-developed research projects with clear aims, strong preliminary rationale, and the capacity to produce publishable, actionable results. At its core, the FOA is designed to strengthen collaborative research that addresses major infectious disease burdens and closely related health challenges in South Africa, while also advancing scientific knowledge that is broadly relevant to global health.
The scientific focus is centered on tuberculosis (TB), HIV/AIDS, and closely connected areas that sit at the intersection of these epidemics. This includes both biomedical research and behavioral science related to HIV/AIDS, as well as HIV-associated comorbidities. The FOA explicitly calls out malignancies as an important category of HIV-related comorbidity, reflecting the reality that immune suppression and chronic infection can increase cancer risk and complicate diagnosis and treatment. In practical terms, the scope is broad enough to include research that ranges from basic and translational science through clinical and population-informed studies, so long as the work is clearly tied to TB, HIV/AIDS, and/or HIV-associated conditions and is grounded in meaningful U.S.-South Africa collaboration.
Administratively, this opportunity is identified as Funding Opportunity Number RFA-AI-14-009 and is categorized as a discretionary grant. It was posted on December 13, 2013, with an application closing date of April 22, 2014, and it was later archived on May 23, 2014. While it is not an active competition now, the details are still useful as a model for how NIH frames bilateral or regional collaborative research programs, including expectations around eligibility, budgets, and research themes.
The FOA listed an estimated total funding level of $8,000,000 and an award ceiling of $350,000. No cost sharing or matching was required, which is typical for many NIH research grants and is meant to reduce barriers to participation and keep the emphasis on scientific merit and feasibility rather than an applicant's ability to contribute non-federal funds.
Eligibility was intentionally broad and included many types of organizations that can conduct biomedical research or support it, such as public and private institutions of higher education, nonprofit organizations (including both 501(c)(3) and certain non-501(c)(3) entities), for-profit organizations (other than small businesses, with small businesses also listed as eligible), and a range of government entities (state, local, tribal, and special district governments). The announcement also highlighted eligibility for organizations that serve specific populations or have specific missions, including Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions, along with faith-based and community-based organizations where appropriate.
A key feature of this FOA is how it treats non-U.S. participation. Non-domestic entities (foreign organizations and foreign institutions) from South Africa were eligible to apply, which aligns directly with the program's bilateral intent. At the same time, it clarified that non-domestic components of U.S. organizations were not eligible to apply as applicants, although foreign components (as defined by the NIH Grants Policy Statement) were allowed. In effect, the FOA was designed to make it feasible for South African institutions to serve as direct applicants while still maintaining NIH policy boundaries around what constitutes an eligible applicant organization and how foreign involvement is structured.
The opportunity falls under multiple CFDA numbers, reflecting its cross-cutting relevance to infectious diseases, microbiology, mental health, child health, and cancer research, including cancer cause and prevention, detection and diagnosis, treatment, biology, and control. That mix signals that NIH anticipated proposals spanning multiple disciplines and institutes, especially where HIV intersects with oncology, mental health, and other complex health outcomes.
For applicants and research teams, the practical takeaway is that this program aimed to fund rigorous, collaborative projects that combine complementary expertise and infrastructure across the U.S. and South Africa, with a clear emphasis on conditions that remain among the most pressing drivers of morbidity and mortality in the region. The full archived announcement was hosted by NIH at the link provided in the source material, and NIH’s Office of Extramural Research (OER) webmaster contact was listed for access or technical issues related to the posting.
FAQs: U.S. South Africa Program for Collaborative Biomedical Research (R01) (RFA-AI-14-009)
What is the U.S. South Africa Program for Collaborative Biomedical Research (R01)?
This is a National Institutes of Health (NIH) grant opportunity designed to build and support sustained, high-quality biomedical research partnerships between investigators and institutions in the United States and South Africa. It uses the NIH R01 mechanism and is intended to support well-developed research projects that can produce publishable, actionable results.
What is the funding opportunity number for this program?
The Funding Opportunity Number is RFA-AI-14-009.
What type of grant is this?
It is categorized as a discretionary grant and is structured around the NIH R01 mechanism.
What does it mean that this opportunity uses the NIH R01 mechanism?
It means the program is intended for well-developed projects with clear research aims, a strong preliminary rationale, and the capacity to produce results that are publishable and actionable.
What is the main purpose of this FOA?
The core purpose is to strengthen collaborative U.S.-South Africa research that addresses major infectious disease burdens and closely related health challenges in South Africa, while also advancing scientific knowledge relevant to global health.
What diseases or topics are the main scientific focus areas?
The scientific focus centers on tuberculosis (TB), HIV/AIDS, and closely connected areas at the intersection of these epidemics. It also includes biomedical and behavioral science related to HIV/AIDS and HIV-associated comorbidities.
Are HIV-associated comorbidities within scope?
Yes. The FOA includes HIV-associated comorbidities as part of the scope.
Are malignancies (cancers) considered relevant under this FOA?
Yes. The FOA explicitly identifies malignancies as an important category of HIV-related comorbidity.
What kinds of studies does the FOA allow (basic, clinical, population, etc.)?
The scope is broad enough to include research ranging from basic and translational science through clinical and population-informed studies, as long as the work is clearly tied to TB, HIV/AIDS, and/or HIV-associated conditions and is grounded in meaningful U.S.-South Africa collaboration.
Does the FOA require U.S.-South Africa collaboration?
Yes. A central feature is sustained collaboration between U.S. and South African investigators and institutions, combining complementary expertise and infrastructure.
When was this opportunity posted and when did it close?
It was posted on December 13, 2013, and the application closing date was April 22, 2014.
Is this funding opportunity still active?
No. It was archived on May 23, 2014, and is not an active competition now.
Why is an archived FOA still useful?
The details can still serve as a model for how NIH frames bilateral or regional collaborative research programs, including expectations around eligibility, budgets, and research themes.
What was the estimated total funding level for this FOA?
The FOA listed an estimated total funding level of $8,000,000.
What was the award ceiling?
The award ceiling was $350,000.
Was cost sharing or matching required?
No. The FOA stated that no cost sharing or matching was required.
What types of organizations were eligible to apply?
Eligibility was broad and included public and private institutions of higher education, nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) entities), for-profit organizations (other than small businesses, with small businesses also listed as eligible), and government entities such as state, local, tribal, and special district governments.
Were organizations with specific missions or serving specific populations highlighted as eligible?
Yes. The announcement highlighted eligibility for organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions. It also referenced faith-based and community-based organizations where appropriate.
Were South African institutions eligible to apply directly?
Yes. Non-domestic entities (foreign organizations and foreign institutions) from South Africa were eligible to apply, consistent with the program's bilateral intent.
Are non-domestic components of U.S. organizations eligible to apply as applicants?
No. The FOA clarified that non-domestic components of U.S. organizations were not eligible to apply as applicants.
Are foreign components allowed under this FOA?
Yes. The FOA indicated that foreign components (as defined by the NIH Grants Policy Statement) were allowed.
What do the listed CFDA numbers indicate about the scope?
The opportunity fell under multiple CFDA numbers across areas such as infectious diseases, microbiology, mental health, child health, and cancer research (including cause and prevention, detection and diagnosis, treatment, biology, and control). This mix signals that NIH anticipated multidisciplinary proposals, especially where HIV intersects with oncology, mental health, and other complex outcomes.
What is the overall takeaway for applicants and research teams?
The program aimed to fund rigorous, collaborative projects that combine complementary expertise and infrastructure across the U.S. and South Africa, with a clear emphasis on TB, HIV/AIDS, and HIV-associated conditions that drive morbidity and mortality in South Africa.
Where was the full announcement hosted and who was listed for technical posting issues?
The full archived announcement was hosted by NIH via the link provided in the source material, and NIH's Office of Extramural Research (OER) webmaster contact was listed for access or technical issues related to the posting.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health Income Security and Social Services
Next opportunity: U.S South Africa Program for Collaborative Biomedical Research (R21)
Previous opportunity: Short term Mentored Career Enhancement Award in Oral, Dental and Craniofacial Research for Mid Career and Senior Investigators (K18)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 14 009
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 14 009) also looked into and applied for these:
| Funding Opportunity |
|---|
| U.S South Africa Program for Collaborative Biomedical Research (R21) Apply for RFA AI 14 010 Funding Number: RFA AI 14 010 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $200,000 |
| Mentored Research Scientist Development Award (Parent K01) Apply for PA 14 044 Funding Number: PA 14 044 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Direct Phase II SBIR Grants to Support Biomedical Technology Development Apply for PAR 14 088 Funding Number: PAR 14 088 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Design and Development of Novel Technologies for Healthy Independent Living (R21) Apply for PAR 14 119 Funding Number: PAR 14 119 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $200,000 |
| Technologies for Healthy Independent Living (R01) Apply for PAR 14 118 Funding Number: PAR 14 118 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| NIH Blueprint Program for Enhancing Neuroscience Diversity through Undergraduate Research Education Experiences (R25) Apply for RFA NS 14 010 Funding Number: RFA NS 14 010 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Limited Competition for NIH Industry Program Discovering Pediatric New Therapeutic Uses for Existing Molecules (UH2/UH3) Apply for PAR 14 210 Funding Number: PAR 14 210 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Limited Competition for NIH Industry Program Discovering New Therapeutic Uses for Existing Molecules (UH3) Apply for PAR 14 211 Funding Number: PAR 14 211 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Limited Competition for NIH Industry Program Discovering New Therapeutic Uses for Existing Molecules (UH2/UH3) Apply for PAR 14 212 Funding Number: PAR 14 212 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Pre application for the NIH Industry Program Discovering New Therapeutic Uses for Existing Molecules (X02) Apply for PAR 14 213 Funding Number: PAR 14 213 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Research on Chronic Overlapping Pain Conditions (R21) Apply for PA 14 243 Funding Number: PA 14 243 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $200,000 |
| Basic Research on HIV Persistence (R21) Apply for PAR 14 248 Funding Number: PAR 14 248 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $200,000 |
| Basic Research on HIV Persistence (R01) Apply for PAR 14 247 Funding Number: PAR 14 247 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Discovery of in vivo Chemical Probes (R01) Apply for PAR 14 279 Funding Number: PAR 14 279 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| U.S. China Program for Research Toward a Cure for HIV/AIDS (R01) Apply for RFA AI 14 057 Funding Number: RFA AI 14 057 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $1,350,000 |
| High Throughput Screening (HTS) to Discover Chemical Probes (R21) Apply for PAR 14 283 Funding Number: PAR 14 283 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $200,000 |
| Blueprint Neurotherapeutics Network (BPN) Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44) Apply for PAR 14 292 Funding Number: PAR 14 292 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Blueprint Neurotherapeutics Network (BPN) Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UH2/UH3) Apply for PAR 14 293 Funding Number: PAR 14 293 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Limited Competition Research Training for Career Development of Junior Faculty in Medical Education Partnership Initiative (MEPI) Institutions (D43) Apply for RFA TW 14 003 Funding Number: RFA TW 14 003 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $600,000 |
| Physical Sciences Oncology Network (PS ON) Physical Sciences Oncology Projects (PS OP) (U01) Apply for PAR 15 021 Funding Number: PAR 15 021 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 14 009", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.